Agoracom Blog Home

Posts Tagged ‘Tomas Sipo’

Predictmedix $ $PMEDF Announces a 2-Year Revenue Contract With Flow Alkaline Spring Water for North American Operations $ $ $ $

Posted by AGORACOM at 10:49 AM on Wednesday, April 14th, 2021
PMED PredictMedix

TORONTO, April 14, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce a 24 month, multi-unit contract to deploy Safe Entry Stations throughout the North American operations of Flow Water Inc. (“Flow Alkaline Spring Water” or “Flow”). The partnership marks the successful completion of our initial pilot, as the technology is now scaled and deployed across all of Flow’s operations both in Canada and the USA.

A pioneer in the health and wellness arena, Flow was one of the first in Eastern Canada to partner with Predictmedix and Juiceworks Exhibits (JUICEWORKS) to implement Safe Entry Stations at their Aurora facilities in August 2020. North America’s first socially responsible artisan alkaline water plant, Flow continues its spirit of innovation by incorporating AI-powered solutions to improve operational efficiencies.

Initially deployed as a beta site, Safe Entry quickly became an integral part of Flow’s health and safety protocol. The autonomous nature of the technology and the robust multi-symptom screening imparted an added sense of security among their workforce.

As part of their ongoing commitment to their valued staff, they have entered into a multi-unit revenue contract for two years and will now be expanding the program to their remaining facilities in Aurora, Ontario and Verona, Virginia.

“Implementing Safe Entry at our plants has dramatically decreased our absenteeism and increased employee peace of mind. Keeping our staff safe is top priority, and as such, we were determined to implement the best available solution, which we found in Safe Entry,” affirms Nicholas Reichenbach, Founder & Executive Chairman of Flow.

Read More:

Predictmedix $ $PMEDF and JUICEWORKS Form Strategic Partnership with CONNECTUS Global to Deploy Safe Entry Stations Nationwide $ $ $ $

Posted by AGORACOM at 9:09 AM on Monday, April 5th, 2021
PMED PredictMedix

TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce a partnership to deploy Safe Entry Stations in partnership with North American industry leaders JUICEWORKS EXHIBITS (JUICEWORKS) and CONNECTUS Global.

SAFE ENTRY STATIONS leverage military-grade multispectral cameras paired with Predictmedix’s proprietary, clinically based artificial intelligence algorithms. They provide an immediate assessment of individuals looking to access shared spaces by checking for multiple symptoms associated with infectious diseases such as COVID-19.

This ground-breaking technology is poised to change the way we look at screening and, eventually, the diagnosis of infectious diseases. Autonomous, comprehensive analysis provides peace of mind to individuals entering shared spaces, be it for work, entertainment, or necessity.

Mike Anderson, CEO of CONNECTUS Global, commented:

“Seeing this level of innovation is exciting to drive adoption of digital processes throughout the public and private sectors, what PREDICTMEDIX and JUICEWORKS are doing is revolutionary to introduce a new level of health measurement into the community.”

Read More:

Predictmedix Inc. $ $PMEDF Announces Engagement of Investment Banking Firm Kingswood Capital Markets $ $ $ $

Posted by AGORACOM at 10:14 AM on Monday, March 29th, 2021
PMED PredictMedix

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), a leader in providing AI-powered healthcare solutions is pleased to announce that it has appointed Kingswood Capital Markets (“Kingswood”) in preparation to become a NASDAQ-listed company.

The acceptance of the application to list the Company’s common shares on NASDAQ will be subject to a number of regulatory and listing requirements, including without limitation: retaining the required number of market makers for the Company’s common shares; the filing of the applicable registration statement with the U.S. Securities and Exchange Commission to become a reporting company under the U.S. Securities Act; and the review of the Company and acceptance for listing by NASDAQ. There can be no assurance that NASDAQ acceptance will be granted should the Company submit its listing application.

Kingswood Capital Markets is a global full-service middle market investment bank. Kingswood helps its clients grow through optimal capital raising structures. Its team of experienced investment professionals has collectively financed over $50 billion in public and private capital markets and provides strategic solutions to clients across a wide spectrum of industries.

Kingswood’s expertise has been engaged to aid in both Predictmedix’s NASDAQ uplist and business growth, as part of the Company’s endeavors to disrupt the current healthcare and technology market in a safe, non-invasive, and economically sustainable way.

Read More:

Predictmedix Inc. $ $PMEDF Announces LOI to Acquire Symp2pass Inc.

Posted by AGORACOM at 1:44 PM on Tuesday, March 23rd, 2021
PMED PredictMedix

TORONTO, March 23, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce it has entered into a letter of intent (the “LOI”), to acquire Symp2Pass Inc. (“Symp2pass”) (the “Acquisition”). The LOI was executed on February 24, 2021 and currently Predictmedix and Symp2pass are working on the definitive agreement.

Symp2Pass is a profitable, revenue generating AI powered IoT product suite of technologies developed by SmartCone Technologies Inc. Symp2Pass had revenues of $2.27 million for the fiscal year ending December 31, 2020 (unaudited) with earnings before taxes of approximately $205,000.

Symp2Pass is one of the first end-to-end advanced touchless health and wellness testing solutions that currently provides advanced COVID-19 symptom screening from multiple independent sensors with geolocation mapping making it unique and more reliable than a single test or measurement. Much like Predictmedix’s Safe Entry Station units, Symp2Pass affords hardware product installation that is coupled with scalable, AI powered software technologies. Beyond the standard questionnaire based screening tools, Symp2Pass measures actual temperature, capable of cough identification, and scent recognition, all critical parts of a more effective screening.

Symp2Pass also affords integration capabilities with other IoT products such as RFID bracelets and QR Codes and associated scanners that can assist workplaces in comprehensive employee tracking, tracing, and reporting tying those initial measurements for individuals with multiple automated measurements in various situations during the day. The data collected from the hardware components are immediately uploaded on the cloud and is synthesized with AI-powered technologies within seconds to deliver instant results.

The strategic acquisition will catalyze growth prospects for Predictmedix and will allow the company to offer world class products in line with our mission of becoming the first line of defense in improving workplace health and safety.

Read More:

Predictmedix Inc. $ $PMEDF Secures Strategic Financing to Catalyze Operations

Posted by AGORACOM at 10:37 AM on Friday, March 5th, 2021

TORONTO, March 05, 2021 — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to provide a corporate update on its recent activities. The Company is proud to announce that it has closed a non-brokered private placement for gross proceeds of $1,090,085 in a strategic financing round to catalyze the Company’s operations as it scales its business.

A total of 3,114,529 units were issued at a price of $0.35 each. Each unit is comprised of one common share of the Company and one warrant, with each warrant exercisable into a common share at an exercise price of $0.50 per share for a period of two years.

The shares and warrants comprising the units issued pursuant to the offering are subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws.

Predictmedix recently entered the live event space with the deployment of our Safe Entry Solutions unit at the Superbowl after-party held at Tampa Bay, Florida.

The event was incredibly successful, as our product deployments were able to immediately detect an individual that exhibited symptoms for COVID-19. The story received national press coverage and made the front page of Tampa Bay Times, reaching over 1.6 million weekly readers.

Read More:

Predictmedix Inc. $ $PMEDF Announces Results of its Annual and Special Meeting of Shareholders

Posted by AGORACOM at 5:16 PM on Friday, January 29th, 2021
  • Sheldon Kales, Rahul Kushwah, Tomas Sipos and Ajit Kumar re-elected as directors of the company.

TORONTO, ON / ACCESSWIRE / January 29, 2021 / Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the”Company“) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on January 28, 2021 at 10:00 a.m. (the “Meeting“). The requisite approval of shareholders for the following items, all as more particularly described in the information circular of the Company dated December 21, 2020 (the “Circular“), was received at the Meeting:

1. setting the number of directors of the Company at four;

2. the re-election of Sheldon Kales, Rahul Kushwah, Tomas Sipos and Ajit Kumar as directors of the Company for the ensuing year;

3. the re-appointment of Harbourside CPA LLP (previously Buckley Dodds LLP) as the Company’s auditors; and

4. the authorization of the Company to make an application to the Supreme Court of British Columbia pursuant to Section 229 of Business Corporations Act (British Columbia) (“Section 229 Application“).

The only omissions, defects, errors or irregularities the Company sought to rectify through the Section 229 Application was the Company’s failure to hold an annual general meeting during the 2019 calendar year and distribute interim and annual financial statements. There were no other undisclosed omissions, defects, errors or irregularities that Predictmedix needed to cure.

Read more: